Lobbying client · LD-2 disclosures
Kyverna Therapeutics, Inc.
California
5 filings from 2 registrants · 2025–2026 · latest filed Jul 20, 2026
Reported on its behalf
$250K
every LD-2 on file
Its own filed spend
$0
lobbying for itself
Fees to outside firms
$250K
across every firm on file
Spend over time
Every filing period on record, as reported. One column per filed period — a period with no column is a period with no filing, not a zero.
Basis · Amendments and terminations supersede the original report for the same registrant, client and period, so a revised quarter is counted once at its latest filed value. Registration-only filings carry no activity money and are excluded from these totals.
Who lobbies for them
Every outside firm that has filed on this client's behalf, by fees reported.
What they lobby on
Issue areas declared on the filings, ranked by how many filings name each one.
Health Issues
HCR
3 filings
$170K on those filings
Pharmacy
PHA
2 filings
$80K on those filings
Note · A filing names one to several issue areas and reports a single dollar figure for the period, so the same money appears beside every issue that filing declares. The dollar column is therefore — it is not a split of the total, and these figures sum above it. Filing counts do not double-count.
Bills named in the filings
Every bill reference extracted from the filings' activity descriptions.
- H.R. 8646 119th CongressAgriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 20271 filingthrough 2026
How these are found · Bill references are extracted from the free-text activity description each filing writes, then matched to the Congress in session that filing year. A reference we can't match to a bill on file is still shown, unlinked — we cite what the filing said rather than guess at what it meant. Naming a bill is not a position on it: LD-2 records that a client lobbied on the bill, never which side.
Who did the lobbying
Every lobbyist named on this client's filings.
- Anna Abram Akin Gump Strauss Hauer & FeldCovered position: Dpty Comm, Pol, Leg, Intnl Affrs, FDA, Mar19Jan21; Mar17Mar19; Spcl Asst HHS, Jan21Mar17; Dec09Jan21; Hlth Dirctr, Sen Burr, Sen Hlth, L&P Comm, Apr09Dec09; Stff Mbr, Sen VA Comm, Feb09Apr09; AsstDrctr, WH Jan0709; LA, LC, SA, SenSantorum, May03Dec064 filingsthrough 2026
- Kandis Mcclure Akin Gump Strauss Hauer & FeldCovered position: Intern for Sen. Harry Reid, Jan. - Apr. 2013.4 filingsthrough 2026
- Emily Felder Brownstein Hyatt Farber Schreck, LLPCovered position: Director of the Office of Legislation, CMS; Counsel, House Energy and Commerce Committee; Counsel, Senate Committee on Homeland Security and Government Affairs; Counsel, House Oversight and Government Reform Committee3 filingsthrough 2026
The filings
Every filing on record. Each row links to its full disclosure.
This record groups every filed spelling of the client's name into one entity, so "MERCK & CO., INC." and "MERCK & CO INC" read as the same company. The grouping is the client's normalized name — organizations that file under genuinely different names appear separately. Handle: kyverna-therapeutics-inc.